Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders
doi.org/10.1016/j.cl...
🆒So proud to have contributed to this work: Modulation of prefrontal NMDA receptors reveals pharmacogenetic differences between SHR and SLA16 rat strains
www.sciencedirect.com/science/arti...
Reframing nociplastic pain research and treatment using post-traumatic stress disorder–inspired conceptual models
journals.lww.com/pain/fulltex...
Acute and post-acute neurobehavioral responses to LSD in healthy subjects: a randomized controlled study
www.nature.com/articles/s41...
Differences in brain activation associated with fear learning and memory in trauma survivors who did or did not develop posttraumatic stress disorder over one year after trauma
doi.org/10.1016/j.ps...
Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems | ACS Pharmacology & Translational Science pubs.acs.org/doi/10.1021/...
Inhibiting fear memory recall-induced oligodendrogenesis rescues PTSD-like behaviors
www.nature.com/articles/s41...
Ten practical suggestions for setting up a psychedelic study
journals.sagepub.com/doi/10.1177/...
Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the US
doi.org/10.1080/0279...
Anxiolytic and sedative drugs: Sleep modulation and memory implications
www.sciencedirect.com/science/arti...
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
Bertoglio lab (FMC/UFSC)
doi.org
www.nature.com
Neuropsychopharmacology - Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study
Given the increases in psychedelic use, we examined correlates of psychedelic use and use motives among US young adults. In 2025, adults ages 18–34 (n = 3,227; Mage = 26.38, ~50% past-month cannabi...
Sleep plays a crucial role in cognitive processes, particularly in memory consolidation, with Non-Rapid Eye Movement (NREM) and Rapid Eye Movement (RE…
Classic serotonergic psychedelics-such as lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT)-hold remarkable promise for treating neuropsychiatric disorders, yet their clinical translation is severely constrained by first-pass metabolism, erratic pharmacokinetics, unsuitable action profiles, and off-target peripheral serotonin effects. To overcome these barriers, advanced delivery systems─such as transdermal and microneedle patches, intranasal sprays, sublingual films, and injectable formulations─have been developed, alongside molecular strategies including prodrugs, “off-switch” 5-HT receptor antagonists for session control, selective receptor bias, and adjunctive pharmacological approaches. These innovations help bypass hepatic metabolism, enable precise control over onset and duration of action, and minimize peripheral receptor activation. Preclinical and early clinical evidence shows gains in bioavailability, half-life extension, and conversion of fleeting psychedelic effects into manageable windows. These platforms offer a path to safer, patient-centered therapies. Despite regulatory and trial-design challenges, delivery innovations provide the essential pharmacokinetic toolkit to advance the field and clinical adoption.
The therapeutic potential of psychedelics is currently being explored in a range of neuropsychiatric conditions. Nevertheless, their designation as Schedule 1 s...
